Oligopeptide-10

Oligopeptide-10 is a synthetic cosmetic peptide whose sequence is derived from granulysin, a naturally occurring antimicrobial peptide involved in the body's immune defenses. In cosmetics it is used as a topical ingredient, most often in formulas aimed at blemish-prone or acne-prone skin.

Oligopeptide-10 is a cosmetic ingredient, not an injectable therapeutic and not an approved drug. Its role is limited to leave-on or rinse-off skincare products applied to the surface of the skin, where it is included for its studied antibacterial and skin-clarifying properties.

Because Oligopeptide-10 is modeled on an antimicrobial peptide, the properties that interest formulators are surface-level and topical. High-level themes described in cosmetic-ingredient literature include:

• Antibacterial activity relevant to the skin surface, including bacteria associated with blemishes
• A skin-clarifying or purifying role that supports the appearance of clearer skin
• Compatibility with other topical ingredients in blemish-focused formulas

These are cosmetic, surface-directed properties. Oligopeptide-10 is not intended to act systemically, and cosmetic claims are distinct from drug claims about treating disease.

Oligopeptide-10 appears as an ingredient in topical skincare, particularly products marketed for acne-prone, oily, or blemish-prone skin. In this context it is used to support skin clarity and a cleaner-looking complexion rather than as a medical acne treatment.

As a cosmetic ingredient, it is regulated under cosmetic frameworks rather than as a drug in major markets. Products should be used according to their labeling, and cosmetic use is separate from any approved medical therapy for acne or skin conditions.

Because Oligopeptide-10 is applied to the skin as a cosmetic and is not intended to enter systemic circulation or influence performance, it does not fall into the categories that anti-doping programs are designed to address. It is not associated with the growth-factor, hormone, or metabolic pathways that dominate the WADA Prohibited List.

Athletes with specific compliance questions should still confirm the status of any product's full ingredient list with the relevant anti-doping authority.

Topically applied peptides used in cosmetics are generally associated with local rather than systemic considerations. Possible issues discussed for skincare ingredients in general include local irritation, redness, or sensitivity, especially for reactive or compromised skin.

Patch testing a new product and reviewing the complete ingredient list are common-sense cosmetic practices. Anyone with a skin condition or known sensitivities should consult a dermatologist rather than relying on general educational summaries.

Oligopeptide-10 is used as a topical cosmetic ingredient, so the relevant concepts are about formulation and surface application rather than systemic dosing.

This summary describes how the ingredient is used in cosmetics and does not constitute medical advice.

Oligopeptide-10 is an INCI (ingredient-labeling) name, not a specific tested product. It reaches consumers only inside finished serums, gels, and lotions, and it is normally supplied to formulators as a dilute trade blend rather than as neat peptide — so a percentage on a supplier datasheet describes the blend, not the peptide.

In blemish-focused formulas it is typically paired with ingredients that carry their own regulatory status. In the United States, benzoyl peroxide (2.5–10%), salicylic acid (0.5–2%), and sulfur (3–10%) are recognized acne drug active ingredients under the over-the-counter monograph at 21 CFR 333, Subpart D; a peptide included for "clarifying" appearance claims is a cosmetic. A single bottle can therefore contain both an OTC acne drug and a cosmetic peptide, and improvement reported by a user cannot be attributed to one rather than the other.

That mixed-formula problem also runs through the published work. The most informative clinical study of a granulysin-derived peptide gave every participant systemic isotretinoin and varied only whether topical peptide was added (Ma et al., J. Cosmet. Dermatol., 2022), so the peptide's independent contribution was never isolated.

Interest in Oligopeptide-10 stems from the antibacterial biology of granulysin, the antimicrobial peptide it is derived from, and from cosmetic research into peptides for blemish-prone skin. This work supports its use as a clarifying-type cosmetic ingredient.

As with many cosmetic ingredients, marketing claims can extend beyond what controlled evidence supports. Cosmetic benefits relate to skin appearance and should not be interpreted as treatment of any medical condition. High-level overviews are not a substitute for critical appraisal of the underlying data.

For deeper dives on this cosmetic peptide, see:

• Oligopeptide-10 areas of cosmetic interest
• Oligopeptide-10 skin tolerance and safety context
• Oligopeptide-10 formulation concepts (educational)
• Oligopeptide-10 research and evidence overview

What is granulysin, and why build a skincare peptide from it? Granulysin is a human antimicrobial protein released by cytotoxic immune cells. Researchers at UCLA and elsewhere synthesized short fragments of it — called granulysin-derived peptides, or GDPs — and showed that fragments carrying a helix-loop-helix motif killed Cutibacterium (formerly Propionibacterium) acnes in vitro, killed it inside isolated human microcomedones, and suppressed the cytokine release that C. acnes provokes (McInturff et al., J. Invest. Dermatol., 2005). The stated motivation was antibiotic resistance: the peptides were bactericidal, which the authors framed as an advantage over bacteriostatic antibiotics.

Is the research on "Oligopeptide-10" specifically? This is the distinction that most ingredient write-ups skip. The published literature studies granulysin-derived peptides identified by laboratory codes — GDP, peptide 31-50v44w, GDP-20 — not an ingredient named Oligopeptide-10. The INCI name is a labeling designation, and no peer-reviewed trial has been published under it. Reading the GDP literature as evidence for a product labeled Oligopeptide-10 requires assuming the materials are equivalent, which the papers do not establish.

What did the human GDP studies actually find? Two, both small and neither placebo-controlled. Lim and colleagues screened 20 synthesized GDPs for antimicrobial activity, then had 30 patients with facial acne apply a topical formulation containing 50 ppm of the best-performing peptide twice daily for 12 weeks: pustule counts and Korean Acne Grading System scores fell significantly, but comedone counts rose, and there was no control group (Int. J. Dermatol., 2015). In a 60-patient Russian study, adding topical GDP-20 to low-dose systemic isotretinoin produced substantial lesion reduction over 12 weeks — but both arms received isotretinoin, a potent approved drug, so the peptide's own contribution cannot be read off the result (J. Cosmet. Dermatol., 2022).

Is it a substitute for acne medication? No, and the difference is legal as well as clinical. The FDA defines a drug partly by intended use — "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" — so a product marketed to treat acne is a drug regardless of how it is packaged (FDA, Is It a Cosmetic, a Drug, or Both?). Cosmetic ingredients other than color additives need no FDA approval before marketing (FDA). A cosmetic peptide sold for the appearance of clearer skin is making a deliberately narrower claim than benzoyl peroxide or a prescription retinoid.

Who funded the underlying research? Worth knowing before weighing it. The 2005 granulysin-peptide paper carries a conflict-of-interest statement noting that several authors were employees, consultants, or scientific advisory board members of Ansata Therapeutics, the company developing the peptides (J. Invest. Dermatol., 2005). That is normal for translational work and does not invalidate it, but it means the ingredient's foundational data were produced by parties with a commercial stake, and no independent group has replicated the clinical findings.